Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 randomized double-blind trial of EB-1020 XR in adults with ADHD
jRCT2071250001Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in AISRS total score at Week 6. Started Apr 2025; status: recruiting.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2071250001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250001.